Cargando…
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab
Nivolumab is one of the most commonly used monoclonal antibodies for advanced non-small cell lung cancer treatment, to the extent that the presence of its anti-antibody is considered a negative prognostic factor. Vitamin D (VD) modulates expression of the genes involved in drug metabolism and elimin...
Autores principales: | Cusato, Jessica, Genova, Carlo, Tomasello, Cristina, Carrega, Paolo, Ottonello, Selene, Pietra, Gabriella, Mingari, Maria Cristina, Cossu, Irene, Rijavec, Erika, Leggieri, Anna, Di Perri, Giovanni, Dal Bello, Maria Giovanna, Coco, Simona, Boccardo, Simona, Ferlazzo, Guido, Grossi, Francesco, D’Avolio, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357025/ https://www.ncbi.nlm.nih.gov/pubmed/30669662 http://dx.doi.org/10.3390/cancers11010125 |
Ejemplares similares
-
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer
por: Ottonello, Selene, et al.
Publicado: (2020) -
Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
por: Alama, Angela, et al.
Publicado: (2019) -
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Genova, Carlo, et al.
Publicado: (2019) -
Targeted Therapies: Friends or Foes for Patient’s NK Cell-Mediated Tumor Immune-Surveillance?
por: Damele, Laura, et al.
Publicado: (2020) -
The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
por: Dal Bello, M. G., et al.
Publicado: (2019)